In one paragraphArticle in American journal of hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Nikolaos KakaletsisFirst Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.ORCID 0000-0002-5263-1803 Naohisa HosomiDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.ORCID 0000-0001-7486-9700 Tomohisa NezuDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.ORCID 0000-0003-4877-2336 Patrik MichelStroke Center and Neurology Service, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-4954-7579 Thevoz GuillaumeStroke Center and Neurology Service, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Davide StramboStroke Center and Neurology Service, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-4429-2714 Young Seo KimDepartment of Neurology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Wonjae SungDepartment of Neurology, College of Medicine, Hanyang University, Seoul, Republic of Korea.ORCID 0000-0002-4637-5890 Konstantinos VemmosDepartment of Clinical Therapeutics of Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0003-2465-7130 Eleni KorompokiDepartment of Clinical Therapeutics of Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0003-0403-8316 Maurizio AcampaStroke Unit, Department of Medical Sciences, Surgery and Neurosciences, "Santa Maria Alle Scotte" General Hospital, University of Siena, Siena, Italy.ORCID 0000-0003-4149-1785 Jukka PutaalaDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0000-0002-6630-6104 Lauri TulkkiDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0000-0003-2823-8574 Matthias HermannUniversity Heart Center Zurich, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-0694-7719 Protazy RejmerUniversity Heart Center Zurich, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0001-7454-5466 Philip M BathStroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, United Kingdom.ORCID 0000-0003-2734-5132 Lisa J WoodhouseStroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, United Kingdom.ORCID 0000-0002-4472-1999 Vasilios KotsisThird Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece.ORCID 0000-0002-3755-8097 Elpida AthanasopoulouCardiovascular Prevention & Research Unit, Clinic & Laboratory of Pathophysiology, Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0009-0009-6272-7102 Athanase D ProtogerouCardiovascular Prevention & Research Unit, Clinic & Laboratory of Pathophysiology, Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-3825-532X Haralampos MilionisDepartment of Internal Medicine, Medical School, University of Ioannina, University Hospital of Ioannina, Ioannina, Greece.ORCID 0000-0003-3958-2266 George NtaiosFirst Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.ORCID 0000-0002-0629-9248 Christos SavopoulosFirst Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundEstimated pulse wave velocity (ePWV), an easy to calculate proxy of carotid to femoral PWV (cfPWV), can be derived from 24-hour blood pressure monitoring (24h-BPM). Its role in acute ischemic stroke (AIS) has not previously been investigated in large multinational datasets.
methodsA pooled individual patient data analysis from 13 cohorts across seven countries was conducted, including 2933 AIS patients who underwent 24h-BPM during the hyperacute to subacute phase. ePWV was calculated using a validated equation. Associations with clinical characteristics, stroke severity, etiologic subtypes, and outcomes were assessed with logistic regression. The primary outcome was poor functional outcome at 90 days, defined as a modified Rankin Scale (mRS) >2.
resultsPatients with higher ePWV presented with more severe strokes (median NIHSS 7 vs. 3, P < .001) and had poorer outcomes both at 90 days (63.7% vs. 23.7%, P < .001) and discharge (61.9% vs 29.1%, P < .001). ePWV was associated with poor outcome at 90 days (aOR: 1.24, 95% CI: 1.05-1.45) and discharge (aOR: 1.26, 95% CI: 1.12-1.42), per 1 m/s increase in ePWV, after adjustment for conventional risk factors and stroke severity. In patients ≤50 years, ePWV was highest in those with small vessel disease (SVD), who also had more cardiovascular risk factors than other stroke subtypes.
conclusionsePWV derived from 24h-BPM is a simple, widely applicable measure of vascular aging that is associated with functional outcome after AIS. The higher ePWV observed in young patients with SVD underscores a potential early arteriosclerotic burden in this subgroup.
Indexed as
Brain IschemiaCarotid-Femoral Pulse Wave VelocityIschemic StrokePulse Wave AnalysisStrokeVascular StiffnessAgedAged, 80 and overBlood PressureBlood Pressure Monitoring, AmbulatoryFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosis24-hour blood pressure monitoringacute ischemic strokearterial stiffnessestimated pulse wave velocityfunctional outcomeprognosisvascular aging
Identifiers
PMID42345544
PMCPMC13473874
What Socratic holds
Textmetadata
Read underepoch 390